Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fluvoxamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 10/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | SCN5A | Q14524 | 1/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluvoxamine SCHEMBL341698 | 1.00 | SLC6A4 (1.00) | SLC6A4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Fluvoxamine SCHEMBL33983 | 1.00 | SLC6A4 (1.00) | SLC6A4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Fluvoxamine SCHEMBL178609 | 1.00 | SLC6A4 (1.00) | SLC6A4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Fluvoxamine SCHEMBL8674929 | 0.99 | SLC6A4 (0.98) | SLC6A4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Fluvoxamine SCHEMBL5960517 | 0.99 | SLC6A4 (0.98) | SLC6A4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Fluvoxamine SCHEMBL27816994 | 0.98 | SLC6A4 (0.95) | SLC6A4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13090665 | 0.96 | SLC6A4 (0.93) | SLC6A4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Fluvoxamine SCHEMBL5508120 | 0.94 | SLC6A4 (0.89) | SLC6A4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Fluvoxamine SCHEMBL30628144 | 0.92 | SLC6A4 (0.84) | SLC6A4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL17702850 | 0.91 | SLC6A4 (0.84) | SLC6A4CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1680121-A4 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX INC (US) | 2007-12-26 | — | — | EP | disclosed |
| EP-1691811-A1 | COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR IMPROVING SLEEP QUALITY AND TREATING DEPRESSION | Sepracor, Inc. (US) | 2006-08-23 | — | — | EP | disclosed |
| EP-1680121-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | CombinatoRx, Incorporated (US) | 2006-07-19 | — | — | EP | disclosed |
| WO-2005060968-A1 | COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR IMPROVING SLEEP QUALITY AND TREATING DEPRESSION | SEPRACOR INC. (US) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005037203-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2005-04-28 | — | — | WO | disclosed |
| US-6060642-A | TRANSGENIC MICE MODELS FOR GENE FUNCTION, WHEREIN THE TRANSGENIC MICE ARE CHARACTERIZED BY HAVING ALTERED SEROTONIN 5-HT6 RECEPTOR GENE FUNCTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-05-09 | — | — | US | disclosed |